Mycoplasma pneumoniae: gone forever?
Patrick M. Meyer Sauteur, Michael L. Beeton, Sabine Pereyre, Cécile Bébéar, Marie Gardette, Nadège Hénin, Noémie Wagner, Adrien Fischer, Alessandra Vitale, Julie R. Kessler, Corinne Andreutti, Gilbert Greub, Petra Zimmermann, Philipp Agyeman, Christoph Aebi, Michael Buettcher, Marisa Hostettler, Lisa Kottanattu, Valeria Gaia, Frank Imkamp, Adrian Egli, Christoph Berger, Semjon Sidorov, Romy Tilen, Anita Niederer-Loher, Florence Barbey, Ulrich Heininger, Branislav Ivan, Cihan Papan, Sören L. Becker, Johannes Förster, Malte Kohns Vasconcelos, Birgit Henrich, Colin R. MacKenzie, Nathalie Bossuyt, Melissa Vermeulen, Veerle Matheeussen, Mireille van Westreenen, Nelianne J. Verkaik, Marius Vogel, Annemarie M. C. van Rossum, Baharak Afshar, Søren Anker Uldum, Hanne‐Dorthe Emborg, Karolina Gullsby, Miia K. Laine, Ville Peltola, Santtu Heinonen, Henrik Døllner, Frode Gran Width, Andreas Christensen, Danilo Buonsenso, Fernanda Rodrigues, Jorge Rodrigues, Katerina Tsantila, Minos Matsas, Eleni Kalogera, Evangelia Petridou, Ioannis Kopsidas, Darja Keše, Ran Nir‐Paz, Hila Elinav, Ayelet Michael-Gayego, Tomohiro Oishi, Takeshi Saraya, Yu‐Chia Hsieh, Tsung Hua Wu, Matthias Maiwald, Liat Hui Loo, Tanu Sagar, Rama Chaudhry, Larry K. Kociolek, Nadia Rodríguez, David H. Lorenz, Matthew Blakiston
Abstract
Mycoplasma pneumoniae was a common cause of respiratory tract infections before the COVID-19 pandemic, with worldwide incidence of 8·61% from 2017 to 2020, measured by direct test methods.1 However, non-pharmaceutical interventions (NPIs) against COVID-19 drastically lowered the transmission of M pneumoniae. In the short term, the incidence was down to 1·69% between 2020 and 2021. Lower transmission was also observed for other pathogens at the time.1 However, M pneumoniae transmission also showed long-term reductions during periods with relaxed or discontinued NPIs, with an incidence of 0·70% between 2021 and 2022.